Insurance Readiness Before Clinical or Commercial Activity

Insurance should be treated as a risk-control and launch dependency, not an administrative task completed after activity begins. A policy suitable for an office or consulting company may not respond when the business starts sponsoring a clinical investigation, importing devices, holding inventory, distributing products, employing sales personnel, or accepting responsibility for patient or customer losses.

Coverage Must Follow the Risk Profile

The insurance program should be based on a documented assessment of activities, exposures, controls and residual risk. That assessment should consider the likelihood and severity of loss, the company’s risk tolerance, control effectiveness, and which risks should be avoided, reduced, retained, transferred or shared.

A clinical investigation may create sponsor, product, subject-injury, professional-services, shipment, privacy and depot exposures. Insurance planning should reflect the company’s study role and risk allocation, including responsibility for investigational product control, safety reporting, protocol deviations and subject injury.

Coverage should also address limits, exclusions, deductibles, territorial scope, and requirements imposed by sites, research organizations or clinical trial agreements.

Commercial Activity Creates a Different Risk Profile

Product liability coverage should address claims arising from devices after they have been sold, distributed or placed into use. Importation and distribution may also involve complaint handling, adverse-event escalation, recalls, returns, field actions and business interruption.

Insurance is a risk-transfer mechanism. It does not replace quality-system controls, traceability, recall planning or escalation procedures.

Inventory, Facilities and Personnel

A depot, warehouse, office, demonstration area or consignment program introduces property, custody, continuity and concentration risks. Coverage should be reviewed for customer-owned inventory, goods in transit, off-site stock, consigned products, temperature excursions, spoilage, power failure, theft, flood and replacement costs.

Limits and sub-limits should be compared with the maximum probable loss at any facility, vehicle, clinical site or customer location.

Employees and representatives may add workers’ compensation, employers’ liability, commercial auto, cyber, privacy, employment-practices and excess-liability exposures. The review should test whether existing controls reduce risk to an acceptable residual level and whether additional mitigation, contractual transfer or higher limits are required.

Contracts Can Reallocate Risk

Distribution, clinical, lease, logistics and customer agreements often require minimum limits, additional-insured status, waiver of subrogation, primary and non-contributory wording, territorial coverage or extended reporting periods.

These requirements should be reconciled with indemnities, liability caps, exclusions, and responsibility for recalls, product loss, subject injury and data incidents. A certificate of insurance is evidence of a policy; it does not itself create required endorsements or coverage.

Confirm Coverage Before Operations Begin

Insurance readiness requires confirmation that policies are bound, named insureds are correct, material activities and products have been disclosed, required endorsements have been issued, and remaining uninsured or underinsured risks have been consciously accepted.

These matters should be resolved before the first shipment, study procedure, hire, facility use or customer commitment.

Map Risk Ownership and Operational Responsibility

MDD Options can help manufacturers map clinical and commercial activities into a practical risk register, identify control gaps, and clarify which exposures remain with each party.

Through its hybrid model, MDD Options can assume defined importing, depot, distribution, complaint, recall-support and logistics functions within established U.S. infrastructure, reducing the manufacturer’s direct operational risk.

MDD Options can also support coordination with the manufacturer’s broker, counsel, and commercial or study partners so that risk ownership, mitigation measures, insurance requirements and residual risk are clearly documented.